SI-BONE Q3 Revenue Up 14.5% to $55.7M; Operating Cash Flow Turns Positive
SIBN has more than doubled off its 52-week low of $11.48 on elevated volume (5.3× avg).
Summary
Nine-month operating cash flow turned positive at $4.4 million, against $146.3 million in cash and investments, as SI-BONE's Q3 revenue rose 14.5% to $55.7 million and its net loss narrowed to $3.6 million. The quarter also carries a sterility-related recall of 98 iFuse TORQ implants and a loan covenant reset.
Key Events · Earnings and Guidance · SIBN
-
Q3 Revenue Grows 14.5%
Revenue was $55.7 million versus $48.7 million a year ago, driven by a $6.4 million increase in U.S. revenue and a 19.5% rise in procedure volumes.
-
Loss Narrows, Cash Flow Turns Positive
Net loss fell to $3.6 million (-$0.08 per share) from $4.6 million, and nine-month operating cash flow was positive $4.4 million versus negative $2.4 million a year earlier.
-
Balance Sheet Holds $146.3 Million
Cash and marketable securities totaled $146.3 million at September 30, 2026, against $35.7 million of long-term debt; management says existing liquidity funds operations for at least the next 12 months.
-
Implant Recall and Repackaging
A packaging sterility failure led to a voluntary recall of 98 iFuse TORQ implants, with roughly 3,900 implants being repackaged and re-sterilized; the company has not recorded an accrual for the DOJ Anti-Kickback investigation.
Analysis · SIBN · Industrial Applications And Services
The cash swing is the headline here: nine-month operating cash flow turned positive at $4.4 million from negative $2.4 million, leaving $146.3 million in cash and marketable securities and reducing the odds of another equity raise near the stock's 52-week high. Revenue grew 14.5% to $55.7 million and the quarterly net loss narrowed to $3.6 million from $4.6 million a year ago. Two items temper the quarter. Gross margin slipped to 79.3% from 79.8% on site-of-care and procedure mix, and the company is repackaging and re-sterilizing roughly 3,900 iFuse TORQ implants after a packaging sterility failure, 98 of which were recalled. Meanwhile, the Fifth Amendment to the First-Citizens loan pushes the Net Revenue covenant start to June 30, 2027, buying covenant headroom.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SIBN was trading at $23.77 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $11.48 to $23.93. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.